Q-omics provides the consensus-scored MED26 profile across patient tissues and cancer cell-line models. MED26 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MED26 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, MED26 RNA expression shows 20,191 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where MED26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MED26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MED26 survival associations across molecular data types. MED26 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MED26 RNA expression–survival associations across cancer types. High MED26 expression shows unfavorable associations in KIRP, ACC, KICH, LGG and UVM, but favorable associations in HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MED26 RNA expression.
This table summarizes MED26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MED26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MED26 shows higher tumor expression in HNSC, KIRC, COAD, LIHC, BLCA and STAD. The HNSC box plot shows higher MED26 RNA expression in tumor versus normal tissue (log2 FC = +0.694, t-test p < 0.001).
This table shows molecular features associated with MED26 in patient tissues and cancer cell lines. In patient samples, MED26 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MED26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Lymphoma.
